Advertisement
Canada markets closed

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7259
    -0.0004 (-0.06%)
     

  • CRUDE OIL

    83.83
    +1.10 (+1.33%)
     

  • Bitcoin CAD

    85,989.64
    +1,196.83 (+1.41%)
     

  • CMC Crypto 200

    1,299.69
    +414.15 (+46.16%)
     

  • GOLD FUTURES

    2,398.40
    +0.40 (+0.02%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • NASDAQ futures

    17,414.75
    -132.50 (-0.76%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    37,304.19
    -775.51 (-2.04%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

Company News For Dec 20, 2019

Zacks Equity Research

  • Shares of Conagra Brands, Inc. CAG surged 15.9% after the company reported Q2 fiscal 2020 earnings of 63 cents per share, which beat the Zacks Consensus Estimate of 57 cents.

  • Shares of Catalyst Biosciences, Inc. CBIO gained 65.8% after the company announced a license and collaboration deal with Biogen for a dry age-related macular degeneration treatment.

  • Shares of Herman Miller, Inc. MLHR declined 13.6% after the company reported revenues of $674.20 million for its Q2 fiscal 2020, missing the Zacks Consensus Estimate by 3.2%.

  • Shares of Darden Restaurants, Inc. DRI lost 6.3% after the company reported revenues of $2.06 billion for Q2 fiscal 2020, missing the Zacks Consensus Estimate by 0.1%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Conagra Brands Inc. (CAG) : Free Stock Analysis Report
 
Darden Restaurants, Inc. (DRI) : Free Stock Analysis Report
 
Herman Miller, Inc. (MLHR) : Free Stock Analysis Report
 
Catalyst Biosciences, Inc. (CBIO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research